The issue of informed patient consent is a top priority for virtually every biobank review committee these days.
In general terms, biobankers use informed consent aims to accomplish two goals . Informed consent helps:
Most biobankers follow either the broad consent or dynamic consent model to achieve these goals.
In the broad consent model, a donor consents to his/her sample(s) being used once at the beginning of a research experiment. If additional analyses need to be performed or new experiments are designed, the donor isn’t contacted again, provided the new research isn’t a significant deviation from what was agreed to initially. In the dynamic consent model, donors are asked to re-consent to every new experiment or slight change in research.
In theory, a consent model should balance the ethical responsibility of keeping donors informed about the research they’re enabling with the need for researchers to continually explore new frontiers. Unfortunately, though, neither the broad nor dynamic consent model fully achieves that objective, and so biobankers must carefully weigh the advantages and disadvantages of each one. For example, here are a few key points to consider:
For a more in-depth look at the differences between broad and dynamic consent, read “Broad consent versus dynamic consent in biobank research: Is passive participation an ethical problem?” published in the European Journal of Human Genetics.